01:05 , Feb 16, 2017 |  BC Innovations  |  Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Clonidine topical gel: Completed Phase IIb enrollment

BioDelivery completed enrollment of 125 patients in a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating clonidine topical gel applied thrice daily for 12 weeks. BioDelivery has exclusive, worldwide rights from Arcion to develop and commercialize...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

Clonidine: Phase III data

The double-blind, U.S. Phase III RHAPSODY trial in about 260 patients with painful diabetic neuropathy showed that clonidine topical gel missed the primary endpoint of improving average NPRS score from baseline to day 84 vs....
01:06 , Mar 31, 2015 |  BC Extra  |  Clinical News

BioDelivery falls on Phase III miss

BioDelivery Sciences International Inc. (NASDAQ:BDSI) shed $3.38 (24%) to $10.51 on Monday after its clonidine topical gel ( ARC-4558 ) missed the primary endpoint in a Phase III trial to treat painful diabetic neuropathy (PDN)....
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

Clonidine: Phase III amended

BioDelivery Sciences said it will enroll an additional 80 patients in the double-blind, U.S. Phase III RHAPSODY trial to maintain 90% power to detect a statistically significant difference between its clonidine topical gel and placebo....
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

Clonidine: Completed Phase III enrollment

BioDelivery Sciences completed enrollment of 140 patients with functional skin nociceptors in the double-blind, placebo-controlled, U.S. Phase III RHAPSODY trial evaluating clonidine topical gel for 12 weeks. The company expects to complete an interim analysis...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

Clonidine: Phase III started

BioDelivery Sciences began the double-blind, placebo-controlled, U.S. Phase III RHAPSODY trial to evaluate clonidine topical gel in about 140 patients demonstrating functional skin nociceptors. Clonidine topical gel has Fast Track designation from FDA for the...
08:00 , Jan 13, 2014 |  BioCentury  |  Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Centrexion other news

As of Dec. 30, 2013, newco Centrexion Corp. raised $23.5 million from undisclosed investors, according to SEC filings. The company's management team includes Jeffrey Kindler, who was chairman and CEO of Pfizer Inc. (NYSE:PFE, New...
01:07 , Dec 31, 2013 |  BC Extra  |  Financial News

Newco Centrexion raises $23.5 million

Newco Centrexion Corp. (Baltimore, Md.) raised $23.5 million from undisclosed investors, according to SEC filings. The company's management team includes Jeffrey Kindler, who was chairman and CEO of Pfizer Inc. (NYSE:PFE) from 2006-10; and James...